Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-indu-ced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201.
   PubMed Web of Science ®Google Scholar
• Gradishar W, Salerno KE. NCCN guidelines update: breast cancer. J Natl Compr Canc Netw. 2016;14:641–644.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer. 2009;9(5):327–337.
   PubMed Web of Science ®Google Scholar
• Berger JM, Gamblin SJ, Harrison SC, et al. Structure and mechanism of DNA topoisomerase II. Nature. 1996;379(6562):225–232.
   PubMed Web of Science ®Google Scholar
• Tacar O, Sriamornsak P, Dass CR, et al. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157–170.
   PubMed Web of Science ®Google Scholar
• Meredith AM, Dass CR. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 2016;68(6):729–741.
   PubMed Web of Science ®Google Scholar
• Wang C, Sun X, Wang K, et al. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers. Drug Deliv. 2016;23(8):26972702.
   Web of Science ®Google Scholar
• Zhao Y, Huan ML, Liu M, et al. Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance. Sci Rep. 2016;6:35267.
   PubMed Web of Science ®Google Scholar
• Kruh GD, Goldstein LJ. Doxorubicin and multidrug resistance. Curr Opin Oncol. 1993;5:1029–1034.
   PubMedGoogle Scholar
• Ferreira RJ, Dos Santos DJ, Ferreira MJ, et al. P-glycoprotein and membrane roles in multidrug resistance. Future Med Chem. 2015;7(7):929–946.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE, et al. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
   PubMed Web of Science ®Google Scholar
• International Transporter C, Giacomini KM, Huang SM, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215–236.
   PubMed Web of Science ®Google Scholar
• Azarova AM, Lyu YL, Lin CP, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007;104(26):11014–11019.
   PubMed Web of Science ®Google Scholar
• Bugg BY, Danks MK, Beck WT, et al. Expression of a mutant DNA topoisomerase II in CCRFCEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA. 1991;88:7654–7658.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12(9):587–598.
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204.
   PubMed Web of Science ®Google Scholar
• Pearl LH, Schierz AC, Ward SE, et al. Therapeutic opportunities within the DNAdamage response. Nat Rev Cancer. 2015;15(3):166–180.
   PubMed Web of Science ®Google Scholar
• Singh SV, Nair S, Ahmad H, et al. Glutathione S-transferases and glutathione peroxidases in doxorubicin-resistant murine leukemic P388 cells. Biochem Pharmacol. 1989;38:3505–3510.
   PubMed Web of Science ®Google Scholar
• Meijer C, Mulder NH, Timmer-Bosscha H, et al. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992;52:6885–6889.
   PubMed Web of Science ®Google Scholar
• Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23(12):620–633.
   PubMed Web of Science ®Google Scholar
• Rathore R, McCallum JE, Varghese E, et al. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis. 2017;22(7):898–919.
   PubMed Web of Science ®Google Scholar
• Liu L, Yang M, Kang R, et al. DAMP-mediated autophagy contributes to drug resistance. Autophagy. 2011;7:112–114.
   PubMed Web of Science ®Google Scholar
• Yan MM, Ni JD, Song D, et al. Interplay between unfolded protein response and autophagy promotes tumor drug resistance. Oncol Lett. 2015;10(4):1959–1969.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh UK, Chaudhary A, et al. Targeting autophagy to overcome drug resistance in cancer therapy. Future Med Chem. 2015;7:1535–1542.
   PubMed Web of Science ®Google Scholar
• Christowitz C, Davis T, Isaacs A, et al. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer. 2019;19(1):757.
   PubMed Web of Science ®Google Scholar
• Aydinlik S, Erkisa M, Cevatemre B, et al. Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line. Biochim Biophys Acta Gen Subj. 2017;1861(2):49–57.
   PubMed Web of Science ®Google Scholar
• Abdel-Mohsen MA, Abdel Malak CA, El- Shafey ES, et al. Influence of copper (I) nicotinate complex and autophagy modulation on doxorubicin-induced cytotoxicity in HCC1806 breast cancer cells. Adv Med Sci. 2019;64(1):202–209.
   PubMed Web of Science ®Google Scholar
• Gao M, Xu Y, Qiu L, et al. Sensitization of multidrug-resistant malignant cells by liposomes coencapsulating doxorubicin and chloroquine through autophagic inhibition. J Liposome Res. 2017;27(2):151–160.
   PubMed Web of Science ®Google Scholar
• Guo B, Tam A, Santi SA, et al. Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells. BMC Cancer. 2016;16(1). DOI:https://doi.org/10.1186/s12885-016-2790-3
   Google Scholar
• Liu Z, Shi A, Song D, et al. Resistin confers resistance to doxorubicin induced apoptosis in human breast cancer cells through autophagy induction. Am J Cancer Res. 2017 Mar 1;7(3):574–583.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu Z, Wu S, et al. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget. 2017 May 9;8(19):31465–31477.
   PubMedGoogle Scholar
• Wang Z, Liu Z, Wu S, et al. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy. Oncotarget. 2017 May 9;8(19):31465–31477.
   PubMedGoogle Scholar
• Xu XD, Zhao Y, Zhang M, et al. Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin. Int J Mol Sci. 2017;18(2):370.
   PubMed Web of Science ®Google Scholar
• Codogno P, Mehrpour M, Proikas-Cezanne T, et al. Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol. 2011;13(1):7–12.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Pietrocola F, Levine B, et al. Metabolic control of autophagy. Cell. 2014;159(6):1263–1276.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445–544.
   PubMed Web of Science ®Google Scholar
• Subramani S, Malhotra V. Non-autophagic roles of autophagy-related proteins. EMBO Rep. 2013;14(2):143–151.
   PubMed Web of Science ®Google Scholar
• Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42.
   PubMed Web of Science ®Google Scholar
• Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol. 2010;12(9):814822.
   Web of Science ®Google Scholar
• Lin L, Baehrecke EH. Autophagy, cell death, and cancer. Mol Cell Oncol. 2015;2(3):e985913.
   PubMed Web of Science ®Google Scholar
• Glick D, Barth S, Macleod KF, et al. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221(1):3–12.
   PubMed Web of Science ®Google Scholar
• White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401–410.
   PubMed Web of Science ®Google Scholar
• Guo JY, Xia B, White E, et al. Autophagy-mediated tumor promotion. Cell. 2013;155(6):1216–1219.
   PubMed Web of Science ®Google Scholar
• Das CK, Mandal M, Kogel D, et al. Pro-survival autophagy and cancer cell resistance to therapy. Cancer Metastasis Rev. 2018;37(4):749–766.
   PubMed Web of Science ®Google Scholar
• Levy JMM, Towers CG, Thorburn A, et al. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–542.
   PubMed Web of Science ®Google Scholar
• Li YJ, Lei YH, Yao N, et al. Autophagy and multidrug resistance in cancer. Chin J Cancer. 2017;36(1):52.
   PubMedGoogle Scholar
• Kim HJ, Lee SG, Kim YJ, et al. Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells. Int J Oncol. 2013;42(6):1985–1992.
   PubMed Web of Science ®Google Scholar
• Yang L, Yu Y, Kang R, et al. Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells. Leuk Lymphoma. 2012;53(2):315–322.
   PubMed Web of Science ®Google Scholar
• Yang C, Gao R, Wang J, et al. High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy. Tumour Biol. 2014;35(7):63576363.
   Google Scholar
• Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007;117(2):326–336.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Si S, Schoen S, et al. Suppression of autophagy enhances preferential toxicity of paclitaxel to folliculin-deficient renal cancer cells. J Exp Clin Cancer Res. 2013 Dec 4;32(1):99.
   PubMedGoogle Scholar
• Sasaki K, Tsuno NH, Sunami E, et al. Chloroquine potentiates the anticancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 2010;10:370.
   PubMed Web of Science ®Google Scholar
• Xi G, Hu X, Wu B, et al. Autophagy inhibition promotes paclitaxel induced apoptosis in cancer cells. Cancer Lett. 2011;307(2):141–148.
   PubMed Web of Science ®Google Scholar
• Yin L, Xiang Y, Zhu DY, et al. Crystal structure of human SH3BGRL protein: the first structure of the human SH3BGR family representing a novel class of thioredoxin fold proteins. Proteins. 2005;61(1):213–216.
   PubMed Web of Science ®Google Scholar
• Cesareni G, Panni S, Nardelli G, et al. Can we infer peptide recognition specificity mediated by SH3 domains? FEBS Lett. 2002;513(1):38–44.
   PubMed Web of Science ®Google Scholar
• Tong F, Zhang M, Guo X, et al. Expression patterns of SH3BGR family members in zebrafish development. Dev Genes Evol. 2016;226(4):287–295.
   PubMed Web of Science ®Google Scholar
• Werner CJ, Heyny-von Haussen R, Mall G, et al. Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci. 2008;6:8.
   PubMed Web of Science ®Google Scholar
• Van ‘T Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536.
   PubMed Web of Science ®Google Scholar
• Abba MC, Hu Y, Sun H, et al. Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics. 2005;6:37.
   PubMed Web of Science ®Google Scholar
• Muniz Lino MA, Palacios-Rodriguez Y, Rodriguez-Cuevas S, et al. Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9. J Proteomics. 2014;111:198211.
   Web of Science ®Google Scholar
• Li H, Zhang M, Wei Y, et al. SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane. J Exp Clin Cancer Res. 2020;39:81.
   PubMed Web of Science ®Google Scholar
• Majid SM, Liss AS, You M, et al. The suppression of SH3BGRL is important for v-Rel-mediated transformation. Oncogene. 2005;25:756–768.
   Web of Science ®Google Scholar
• Xu L, Zhang M, Li H, et al. SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia. Leuk Lymphoma. 2018;59:918–930.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu B, Al-Aidaroos AQ, et al. Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans. Oncogene. 2016;35:3303–3313.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Autophagy. 2021 Jan;17(1):1–382.
   PubMed Web of Science ®Google Scholar
• Nagaraj N, Wisniewski JR, Geiger T, et al. Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol. 2011;7:548.
   PubMed Web of Science ®Google Scholar
• Maier T, Guell M, Serrano L, et al. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009;583:3966–3973.
   PubMed Web of Science ®Google Scholar
• Coley HM, Amos WB, Twentyman PR, et al. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer. 1993;67:1316–1323.
   PubMed Web of Science ®Google Scholar
• Takagi M, Absalon MJ, McLure KG, et al. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. CELL. 2005;123:49–63.
   PubMed Web of Science ®Google Scholar